Premium Nahrungsergänzungsmittel | artgerecht

Ramipril – ACE Inhibitor for High Blood Pressure

Ramipril is an ACE inhibitor used to treat high blood pressure, heart failure, and to protect the kidneys in diabetic patients. It lowers blood pressure and protects the heart and blood vessels.

Regular tips about health Regular tips about health

Things worth knowing about "Ramipril"

Ramipril is an ACE inhibitor used to treat high blood pressure, heart failure, and to protect the kidneys in diabetic patients. It lowers blood pressure and protects the heart and blood vessels.

What is Ramipril?

Ramipril is a prescription medication belonging to the class of ACE inhibitors (Angiotensin-Converting Enzyme inhibitors). It is one of the most widely used drugs in cardiology and internal medicine. Ramipril is primarily indicated for the treatment of high blood pressure (hypertension), heart failure, and the prevention of cardiovascular events in high-risk patients.

Indications

Ramipril is used in the following conditions:

Arterial hypertension: Reduction of elevated blood pressure
Heart failure: Management of cardiac insufficiency following a myocardial infarction
Diabetic nephropathy: Renal protection in patients with type 2 diabetes and elevated urinary protein excretion
Cardiovascular prevention: Reduction of the risk of myocardial infarction, stroke, and cardiovascular death in high-risk patients
Post-myocardial infarction: Improvement of survival rates and reduction of secondary complications

Mechanism of Action

Ramipril is a prodrug that is converted in the liver to its active metabolite ramiprilat after oral administration. Ramiprilat inhibits the angiotensin-converting enzyme (ACE), which normally converts the inactive angiotensin I into the vasoconstricting angiotensin II.

By inhibiting this enzyme, ramipril produces the following effects:

Reduction of angiotensin II levels in the blood
Dilation of blood vessels (vasodilation)
Lowering of blood pressure
Reduction of cardiac workload (preload and afterload)
Increase in bradykinin levels, contributing to additional vasodilatory effects

Dosage

The dosage of ramipril depends on the indication, body weight, and renal function of the patient. Typical dosage ranges include:

Hypertension: 2.5 mg to 10 mg once daily
Heart failure after myocardial infarction: Starting at 1.25 mg, gradually increased to 10 mg daily
Renal protection in diabetes: 1.25 mg to 5 mg once daily

Ramipril is generally taken once daily and can be taken with or without food. Dose adjustment is required in patients with impaired renal function.

Side Effects

Like all medications, ramipril can cause side effects. The most common include:

Dry irritating cough: Affects up to 10% of patients and is caused by increased bradykinin levels
Dizziness and headache: Especially at the start of therapy due to blood pressure reduction
Elevated potassium levels (hyperkalaemia): Particularly in patients with kidney disease
Renal impairment: Especially in patients with pre-existing kidney conditions or volume depletion
Angioedema: A rare but potentially life-threatening swelling of the face, lips, tongue, or throat

Contraindications

Ramipril must not be used in the following situations:

Hypersensitivity to ACE inhibitors
History of angioedema related to previous ACE inhibitor therapy or hereditary angioedema
Pregnancy (especially from the second trimester onwards) and breastfeeding
Bilateral renal artery stenosis or stenosis of the artery to a single functioning kidney
Concomitant use of aliskiren in patients with diabetes or renal impairment

Drug Interactions

Ramipril may interact with various medications and substances:

Potassium-sparing diuretics and potassium supplements: Increased risk of hyperkalaemia
Non-steroidal anti-inflammatory drugs (NSAIDs): Reduced antihypertensive effect and increased risk of renal impairment
Lithium: Possible increase in lithium blood levels
Antihypertensives and diuretics: Additive blood pressure-lowering effects

References

European Medicines Agency (EMA): Ramipril - Summary of Product Characteristics. EMA, 2023. Available at: www.ema.europa.eu
Williams B. et al. - 2018 ESC/ESH Guidelines for the management of arterial hypertension. European Heart Journal, 2018; 39(33): 3021-3104.
Yusuf S. et al. - Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The HOPE Study Investigators. New England Journal of Medicine, 2000; 342(3): 145-153.

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.